The US anticoagulation therapy market has witnessed a
healthy growth rate during the last decade and is expected to grow at a CAGR of
8.5% between 2017 and 2022 to reach USD 27.83 Billion by 2022. Factors such as
the rising incidence of venous thromboembolism, atrial fibrillation, and
stroke; long-term administration and high volume of recurring sales of
anticoagulation drugs; and increasing demand for novel oral anticoagulants
(NOACs) is driving the growth of this market.
Access Sample
Copy of the Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=114158575
The NOACs segment accounted for the largest share of the
US anticoagulation therapy market for drugs in 2016
The US anticoagulation drugs market is categorized into
NOACs, warfarin (VKA), and other drugs. In 2016, the NOACs segment accounted
for the largest share of the market. Due to the better safety and efficacy of
NOACs as compared to traditional therapies, the adoption of NOACs is higher as
compared to traditional drugs. In addition, key market players such as Portola
Pharmaceuticals (received the FDA approval for its NOAC Betrixaban in July
2017) are focusing on the development of NOACs in order to capitalize on the
growth opportunities presented by this shift in market dynamics. Consequently,
many other companies are also expected to focus on developing more safe and
efficient NOACs in the coming years; this will ensure the continued growth of
this segment.
The in-office testing devices accounted for the largest
share of the US anticoagulation therapy market for PT/INR testing devices in
2016
The global US anticoagulation therapy market for PT/INR
testing devices is segmented into in-office testing devices and home testing
devices. In 2016, the in-office testing devices segment dominated the US
anticoagulation therapy market for PT/INR testing devices. The large share of
this segment is mainly attributed to the large number of patients opting for
in-office testing services. However, the home testing devices segment is
expected to grow at the highest CAGR due to its advantages such as convenience,
time & cost savings, and quick result generation. Additionally, the cost of
test devices and the tests themselves are often reimbursable.
By type of service, the testing services held the largest
market share of the anticoagulation therapy market for clinics in 2016
On the basis of types of services provided, the US
anticoagulation therapy market for clinics is categorized into testing services
and consulting services. In 2016, the testing services segment accounted for
the largest share of the US anticoagulation therapy market for clinics. The
recurring need for PT/INR monitoring is the key factor driving the growth of
this market. However, the shift of patients toward novel anticoagulant agents
and high adoption of home testing devices are expected to restrain the growth
of this market to a certain extent
By type of clinics, hospital associated clinics held the
largest market share of the anticoagulation therapy market for clinics in 2016
On the basis of type of clinics, the US anticoagulation
therapy market for clinics is categorized into hospital associated clinics,
independent clinics, and pharmacy-based clinics. In 2016, the hospital
associated clinics segment accounted for the largest share of the US
anticoagulation therapy market for clinics.
C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer (US), Daiichi Sankyo (Japan), and Portola Pharmaceuticals (US) are the major market players in the US anticoagulation therapy market for drugs while Roche (Switzerland), Abbott (US), Siemens (Germany), Alere (US), and CoaguSense (US) are the major market players in the US anticoagulation therapy market for PT/INR home testing devices.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on
30,000 high growth niche opportunities/threats which will impact 70% to 80% of
worldwide companies’ revenues. Currently servicing 5000 customers worldwide
including 80% of global Fortune 1000 companies as clients. Almost 75,000 top
officers across eight industries worldwide approach MarketsandMarkets™ for
their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are
tracking global high growth markets following the "Growth Engagement Model
– GEM". The GEM aims at proactive collaboration with the clients to
identify new opportunities, identify most important customers, write
"Attack, avoid and defend" strategies, identify sources of
incremental revenues for both the company and its competitors. MarketsandMarkets™
now coming up with 1,500 MicroQuadrants (Positioning top players across
leaders, emerging companies, innovators, strategic players) annually in high
growth emerging segments. MarketsandMarkets™ is determined to benefit more than
10,000 companies this year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research ahead of
the curve.
MarketsandMarkets’s flagship competitive intelligence and
market research platform, "RT" connects over 200,000 markets and
entire value chains for deeper understanding of the unmet insights along with
market sizing and forecasts of niche markets.
Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com